Pulmatrix, a clinical stage biotechnology company, has partnered with Cystic Fibrosis Foundation Therapeutics (CFFT), a nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to advance PUR118 in clinical trials.

The PUR118 is Pulmatrix’s lead iCALM inhaled drug candidate, which is currently in a Phase I study in cystic fibrosis (CF) and two Phase Ib studies in patients with chronic obstructive pulmonary disease (COPD).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

After the completion of Phase I safety and tolerability study in CF patients, Pulmatrix considers initiating a Phase 1b trial of PUR118 in CF patients evaluating mucociliary clearance velocity as an endpoint.

Pulmatrix CEO Robert Clarke said the CF Foundation recognised the potential of PUR118 and is investing with Pulmatrix to increase the drug’s development.

"This is a tremendous vote of confidence in our clinical program and gives us the ability to accelerate our activities as we seek to develop a novel treatment to meet the unmet needs of patients with CF," Clarke said.

See Also:

"Longer term, we see PUR118 as a perfect complement to the existing CF therapies to provide even better patient outcomes."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As per the agreement, Pulmatrix will gain up to $1.4m in upfront and milestone-driven funding from CFFT for the drug development, in addition to introductions to cystic fibrosis academic researchers and access to critical research insight and resources.

The CFFT award is intended to support Pulmatrix’s Phase Ib clinical trials of PUR118 in CF to reduce the risk of acute exacerbations in CF patients.